BR112017012912A2 - prevention of progressive heart failure - Google Patents

prevention of progressive heart failure

Info

Publication number
BR112017012912A2
BR112017012912A2 BR112017012912A BR112017012912A BR112017012912A2 BR 112017012912 A2 BR112017012912 A2 BR 112017012912A2 BR 112017012912 A BR112017012912 A BR 112017012912A BR 112017012912 A BR112017012912 A BR 112017012912A BR 112017012912 A2 BR112017012912 A2 BR 112017012912A2
Authority
BR
Brazil
Prior art keywords
heart failure
prevention
progressive heart
individuals
methods
Prior art date
Application number
BR112017012912A
Other languages
Portuguese (pt)
Other versions
BR112017012912B1 (en
Inventor
Golden Lee
Itescu Silviu
Original Assignee
Mesoblast Int Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014905240A external-priority patent/AU2014905240A0/en
Application filed by Mesoblast Int Sarl filed Critical Mesoblast Int Sarl
Publication of BR112017012912A2 publication Critical patent/BR112017012912A2/en
Publication of BR112017012912B1 publication Critical patent/BR112017012912B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

a presente revelação se refere a métodos para prevenção de insuficiência cardíaca progressiva em indivíduos com disfunção ventricular esquerda (lv) persistente. tais métodos também podem ser usados para tratar ou prevenir a insuficiência cardíaca progressiva em indivíduos com lesão descendente anterior proximal (dap) esquerda e disfunção ventricular esquerda persistente.The present disclosure relates to methods for prevention of progressive heart failure in individuals with persistent left ventricular (LV) dysfunction. Such methods may also be used to treat or prevent progressive heart failure in individuals with left proximal anterior descending (dap) injury and persistent left ventricular dysfunction.

BR112017012912-4A 2014-12-23 2015-12-22 USE OF A POPULATION OF STEM CELLS OR MESENCHYMAL LINEAGE PRECURSORS AND/OR PROGENIES THEREOF AND/OR SOLUBLE FACTORS DERIVED THEREOF IN THE TREATMENT OF PROGRESSIVE HEART FAILURE BR112017012912B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014905240A AU2014905240A0 (en) 2014-12-23 Prevention of progressive heart failure
AU2014905240 2014-12-23
PCT/EP2015/081048 WO2016102601A1 (en) 2014-12-23 2015-12-22 Prevention of progressive heart failure

Publications (2)

Publication Number Publication Date
BR112017012912A2 true BR112017012912A2 (en) 2018-01-02
BR112017012912B1 BR112017012912B1 (en) 2023-05-30

Family

ID=

Also Published As

Publication number Publication date
CA2971514A1 (en) 2016-06-30
JP7379452B2 (en) 2023-11-14
KR20170098862A (en) 2017-08-30
AU2015371011A1 (en) 2017-06-29
JP2022022396A (en) 2022-02-03
WO2016102601A1 (en) 2016-06-30
CN107206027A (en) 2017-09-26
JP2018500346A (en) 2018-01-11
JP7315301B2 (en) 2023-07-26
US20170340674A1 (en) 2017-11-30
US11491188B2 (en) 2022-11-08
JP2024008950A (en) 2024-01-19
EP3237606A1 (en) 2017-11-01
US20230124294A1 (en) 2023-04-20
AU2015371011B2 (en) 2021-07-15
AU2021240329A1 (en) 2021-10-28
SG11201704781XA (en) 2017-07-28

Similar Documents

Publication Publication Date Title
CY1122344T1 (en) BLAUTIA STERCOSIS AND WEXLERAE FOR USE IN THE THERAPEUTIC TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MX2021014709A (en) Methods for increasing red blood cell levels and treating sickle-cell disease.
PH12016501457A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
BR112017006664A2 (en) combination therapies
MX2017010150A (en) Recombinant probiotic bacteria.
MD20170035A2 (en) Compositions and methods of use for treating matabolic disorders
MD20170020A2 (en) Compositions and methods of use for treating metabolic disorders
MY173162A (en) Immune balance regulator
PH12019501010A1 (en) Arginase inhibitor combination therapies
MX2018008709A (en) Therapeutic use of inhibitors of t cell activation or stimulation.
MX2015016100A (en) Cryopyrin inhibitors for preventing and treating inflammation.
BR112017008045A2 (en) compounds as nik inhibitors
PH12018501443A1 (en) Methods of administering hepcidin
MX2016009306A (en) Epicutaneous immunorebalancing.
MX2021007260A (en) Jak1 pathway inhibitors for the treatment of gastrointestinal disease.
MX2017006019A (en) Apilimod for use in the treatment of melanoma.
EA201691567A1 (en) METHODS OF TREATING PULMONARY INJURIES TO THE BRAIN
BR112016015997A2 (en) ? PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND 15- HEPE AND METHODS TO TREAT ASTHMA AND PULMONARY DISORDERS WITH THE USE OF THEM?
MX2019004804A (en) Treatment of prurigo nodularis.
MX2021014120A (en) Treatment of androgen deprivation therapy associated symptoms.
PH12019502315A1 (en) Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
MX2023003924A (en) Methods of administering anti-fibrotic therapy.
PH12019501358A1 (en) Methods of administering hepcidin
BR112017012912A2 (en) prevention of progressive heart failure

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/12/2015, OBSERVADAS AS CONDICOES LEGAIS